Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07641985

Autologous Fat Grafting for Total Breast Reconstruction in Irradiated Breast Cancer Patients

The goal of this clinical trial is to learn whether autologous fat transfer (AFT) is as effective and safe as Deep Inferior Epigastric Perforator (DIEP) flap breast reconstruction in irradiated breast cancer patients following mastectomy. It will also evaluate patient satisfaction, quality of life, complication rates, and cost-effectiveness of both reconstruction techniques. The main questions it aims to answer are:

Does AFT result in non-inferior patient satisfaction with the reconstructed breast compared to DIEP flap reconstruction 12 months after the final operation? Does AFT result in fewer major complications and improved cost-effectiveness compared to DIEP flap reconstruction? Are quality of life outcomes and oncologic safety comparable between AFT and DIEP flap reconstruction in irradiated patients?

Researchers will compare AFT to DIEP flap reconstruction to see if AFT can provide similar reconstructive outcomes with lower morbidity and fewer complications in irradiated breast cancer patients.

Participants will:

Undergo breast reconstruction using either AFT or DIEP flap reconstruction Attend follow-up visits for clinical examinations, imaging, and assessment of complications Complete questionnaires about breast satisfaction, quality of life, and recovery during follow-up Be monitored for oncologic safety and reconstructive outcomes for 12 months after the final operation

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female, aged >18 years.
  • BMI between > 22 and <35 kg/m2
  • History of breast cancer treated with mastectomy (minimally 3 months after mastec-tomy) and post mastectomy chest wall radiotherapy (completed ≥6 months before en-rollment).
  • May include contralateral/bilateral prophylactic mastectomy if at least one side had cancer and radiation.
  • Desires autologous breast reconstruction and accepts randomization between AFT and DIEP.
  • Medically fit for surgery (ASA I-III).
  • Sufficient donor tissue for both AFT (enough fat) and DIEP (suitable abdominal tissue and vasculature).
  • No evidence of active cancer at enrollment; remission confirmed.
  • Able to wear the EVE device (if randomized in AFT).
  • Capable of understanding study information and questionnaires (Dutch or English), willing to give informed consent, and able to comply with follow-up.

Exclusion criteria

  • Prior autologous breast reconstruction on the intended side. BMI <22 or >35 kg/m2
  • Contraindication to DIEP flap (e.g., prior abdominoplasty or abdominal scars affecting perforators).
  • Contraindication to AFT (e.g., insufficient fat or conditions impairing fat graft viability).
  • Current chemotherapy or completed less than 4 weeks prior to enrollment.
  • Serious uncontrolled comorbidities making elective surgery unsafe (e.g., unstable heart disease, severe coagulopathy, end-stage organ failure).
  • Active smoker or not abstinent for at least 6 weeks pre-operatively.
  • Pregnant at time of enrollment.
  • In case low compliance is expected or an inability to comply with study protocol, including unwillingness to undergo either AFT or DIEP, or inability to complete follow-up (due to language, cognitive issues, or relocation plans).
  • Previous enrollment in this trial (patients can only be included once, even if later presenting for contralateral reconstruction).
  • Allergy to lidocaine or silicone

Treatment and study plan

Autologous Fat Transfer

Procedure

Autologous fat transfer as total breast reconstruction

Deep inferior epigastric perforator flap

Procedure

Deep inferior epigastric perforator flap as breast reconstruction

Primary outcomes

  1. to determine whether autologous fat transfer (AFT) is non-inferior to DIEP flap breast re-construction regarding breast satisfaction, as measured by the BREAST-Q, 12 months after the final reconstructive procedure in irradiated breast cancer patients;

    Time frame: 12 months

    One of the primary outcomes is the BREAST-Q "Satisfaction with Breasts" score at 12 months post-reconstruction. This validated, patient-reported measure (0-100 scale) as-sesses satisfaction with breast appearance and feel.

  2. to assess whether AFT is superior to DIEP flap reconstruction in terms of the incidence of major complications requiring reoperation or hospital readmission.

    Time frame: 12 months

    The second primary outcome measure is the incidence of major complications (i.e. complications requiring reoperation or hospital readmission such as hematoma, venous/arterial insufficiency, partial/total flap loss, and infection/abscess).

  3. cost-effectiveness of AFT compared with DIEP flap reconstruction will be evaluated.

    Time frame: 12 months

    The third primary outcome is cost-effective-ness. We will collect detailed healthcare and societal costs per patient using hospital records, CRFs, and a study-adapted patient-reported iMCQ and iPCQ (for health care resource use and productivity loss). QALYs will be calculated from EQ-5D-5L data at multiple timepoints. We will compare cost per QALY (ICER) between AFT and DIEP, and conduct a budget impact analysis.

Secondary outcomes

  1. Physical Well-being: Abdomen (BREAST-Q)

    Time frame: 12 months

    Physical Well-being: Abdomen (donor site), assessed using the BREAST-Q Reconstruction Module. Scores are transformed to a scale ranging from 0 to 100, with higher scores indicating better physical well-being of the abdominal donor site.

  2. Complications (Minor & General)

    Time frame: 12 months

    Incidence of minor recipient-site and donor-site com-plications (i.e. complications taking care of at the outpatient clinic) managed conserva-tively (e.g. wound problems/dehiscence, infection, seroma, hematoma, and abdominal bulging), and any general (systemic) complications related to surgery or hospitalization (e.g. pulmonary embolism, pneumonia).

  3. Oncologic Safety

    Time frame: 12 months

    Monitor and compare breast cancer recurrence rates using routine follow-up and PALGA registry to confirm AFT's oncologic safety.

  4. Sensory Recovery

    Time frame: 12 months

    Evaluate return of breast skin sensation at 12 months with mono-filament testing to compare sensory outcomes between techniques [in MUMC+ only].

  5. Physical Function and Pain

    Time frame: 12 months

    We will assess post-mastectomy pain and phantom sensations using relevant BREAST-Q items or a brief questionnaire. For donor site function, DIEP patients may be asked about core strength (e.g. sit-ups), while AFT patients will be monitored for minor issues like contour irreg-ularities. Assessments will be based on patient reports and clinical exam.

  6. Breast Aesthetics & Volume

    Time frame: 12 months

    Breast volume and shape assessed 12 months after reconstruction using 3D Vectra photography and the BREAST-V volume calculator (https://braflap.com/breast-v/, Sternal Notch - Nipple distance [cm], Fold Projection - Inframammary Fold distance [cm], and Nipple - Inframammary Fold distance [cm]) . Fat graft retention in the AFT group will be estimated by total grafted volume versus final breast volume. Standardized photographs (2D and 3D) will document cosmetic out-comes which can be assessed by a an expert panel.

  7. Radiation-Associated Changes

    Time frame: 12 months

    We will grade radiation fibrosis/telangiectasia in the chest skin at baseline (just before recon) and at 12 months, using the Common Terminology Criteria for Adverse Events (CTCAE) score (for radiation dermatitis/fibrosis). If AFT improves the pliability or vascularity of skin, we might see an improvement in grade (e.g. from CTCAE 2 to 1). If DIEP flap breast reconstruction brings fresh skin, the radiated skin might be partially replaced or supplemented. This is some-what subjective, but we will attempt consistent grading. Also, if any ulcers or non-healing radi-ation damage was present, we will see if healed after reconstruction

  8. Physical Well-being: Chest (BREAST-Q)

    Time frame: 12 months

    Physical Well-being: Chest, assessed using the BREAST-Q Reconstruction Module. Scores are transformed to a scale ranging from 0 to 100, with higher scores indicating better physical well-being of the chest.

  9. Sexual Well-being (BREAST-Q)

    Time frame: 12 months

    Sexual Well-being, assessed using the BREAST-Q Reconstruction Module. Scores are transformed to a scale ranging from 0 to 100, with higher scores indicating better sexual well-being.

  10. Breast Sensation (BREAST-Q)

    Time frame: 12 months

    Breast Sensation, assessed using the BREAST-Q Sensation Module. Scores are transformed to a scale ranging from 0 to 100, with higher scores indicating better breast sensation.

  11. Donor Site Satisfaction (BODY-Q)

    Time frame: 12 months

    Satisfaction with donor site appearance, assessed using the BODY-Q. Scores are transformed to a scale ranging from 0 to 100, with higher scores indicating greater satisfaction with the donor site.

  12. Adverse Effects of Radiation (BREAST-Q)

    Time frame: 12 months

    Adverse Effects of Radiation, assessed using the BREAST-Q Reconstruction Module. Scores are transformed to a scale ranging from 0 to 100. Specify according to the scoring manual whether higher scores indicate fewer or more adverse effects of radiation.

Sponsors and collaborators

Lead sponsor

Maastricht University Medical Center

Other

Collaborators

  • Academisch Ziekenhuis Maastricht

Registry information

Official study title

Autologous Fat Grafting for Total Breast Reconstruction in Irradiated Patients

Acronym: AFT-R

Important dates

Study start
2026
Primary completion
2032
Study completion
2032
First posted
Jun 11, 2026
Registry last updated
Jun 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.